Tresiba (Insulin Degludec) Safety Profile Differences in Black / African Ancestry Patients

Cardiovascular Safety Data From DEVOTE

The DEVOTE trial established the cardiovascular safety of insulin degludec relative to insulin glargine U100 in patients with type 2 diabetes at high cardiovascular risk. The trial enrolled 7,637 participants across 20 countries, and its primary endpoint (first occurrence of major adverse cardiovascular events, or MACE) showed noninferiority for degludec (HR 0.91; 95% CI 0.78 to 1.06) 1.

Racial Subgroup Representation

Black and African ancestry participants made up approximately 6% of the DEVOTE cohort, a proportion that limits the statistical power of race-stratified analyses. The FDA's 2015 approval review noted that "the proportion of Black/African American subjects enrolled in clinical trials was lower than the disease prevalence in this population would warrant" 2. This enrollment gap is common across insulin trials and means that point estimates for safety endpoints in Black subgroups carry wider confidence intervals.

Nocturnal Hypoglycemia Reduction

Across the full DEVOTE population, insulin degludec reduced severe nocturnal hypoglycemia by 40% compared to glargine U100 (rate ratio 0.60; P=0.004) 1. The mechanism is degludec's ultra-flat pharmacokinetic profile, which produces a coefficient of variation for glucose-lowering effect four times lower than glargine U100 3. Race-specific hypoglycemia rates were not separately powered in DEVOTE, but the pharmacokinetic advantage applies regardless of ancestry because the reduced variability is a formulation property, not a patient-dependent pharmacogenomic trait.

Interpreting MACE Outcomes

Black adults with type 2 diabetes carry a disproportionately higher burden of cardiovascular disease. Data from the CDC's National Diabetes Statistics Report show that Black adults are 2.1 times more likely to be hospitalized for diabetes-related cardiovascular complications than White adults 4. This elevated baseline risk means that even when a drug demonstrates noninferiority at the population level, the absolute event rate in Black patients may differ. Clinicians should interpret the DEVOTE cardiovascular signal in the context of each patient's individual risk profile rather than assuming uniform absolute benefit.

Pharmacogenomic Considerations

Pharmacogenomics for insulin therapy differs from small-molecule drugs. Insulin degludec is a recombinant human insulin analog, so CYP450 polymorphisms do not affect its metabolism. The relevant genetic factors for Black and African ancestry patients relate instead to glucose measurement accuracy and comorbidity risk.

HbA1c and Glycation Rate Differences

Multiple studies have documented that HbA1c levels run 0.3 to 0.4 percentage points higher in Black individuals compared to White individuals at the same mean glucose, independent of glycemic control 5. A 2017 analysis in Diabetes Care (N=3,182) confirmed that "race-ethnic differences in glycation rates were observed even after adjusting for multiple measures of glycemia" 5. This discrepancy has direct safety implications for insulin titration. If a clinician titrates degludec to an HbA1c target of 7.0% using HbA1c alone, a Black patient whose true mean glucose is already at target may be over-treated, increasing hypoglycemia risk.

The ADA Standards of Care recommend incorporating continuous glucose monitoring (CGM) or structured self-monitoring of blood glucose (SMBG) data alongside HbA1c for treatment decisions 6. This recommendation carries added weight in populations where the HbA1c-to-glucose relationship is less reliable.

G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects an estimated 10 to 14% of Black males in the United States 7. While G6PD deficiency does not alter insulin degludec's pharmacodynamics or pharmacokinetics directly, it affects red blood cell turnover, which can cause HbA1c to underestimate (not overestimate) true glycemia in individuals with the most severe variants. This creates a paradox: race-related glycation differences push HbA1c higher, but G6PD-related hemolysis pushes it lower. The net effect varies by individual.

For patients with known G6PD deficiency, fructosamine or glycated albumin can serve as alternative glycemic markers 8. These tests reflect average glucose over 2 to 3 weeks rather than 2 to 3 months and are not affected by red blood cell lifespan.

Chronic Kidney Disease and Insulin Degludec Clearance

Black adults in the United States develop end-stage kidney disease at 3.4 times the rate of White adults, according to the United States Renal Data System 9. Diabetes is the leading cause of CKD in this population. The intersection of insulin therapy and declining renal function introduces specific safety considerations for degludec.

Renal Pharmacokinetics

Insulin degludec does not undergo renal clearance in a clinically meaningful way. A dedicated pharmacokinetic study in patients with renal impairment (including ESRD on hemodialysis) found no difference in degludec exposure across eGFR categories 10. The FDA label states that no dose adjustment is required based on renal function 2. This is a practical advantage over some other glucose-lowering drugs (metformin, SGLT2 inhibitors) that require dose modification or discontinuation as eGFR declines.

Hypoglycemia Risk in CKD

Despite the lack of a pharmacokinetic interaction, patients with CKD stages 3 to 5 are at substantially higher risk of hypoglycemia. Reduced renal gluconeogenesis, impaired counter-regulatory hormone responses, and decreased insulin clearance by the kidney all contribute 11. The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guideline recommends that "HbA1c targets be individualized, particularly in patients with advanced CKD, where the risk of hypoglycemia is increased" 12.

Monitoring Protocol Adjustments

For Black patients with eGFR <45 mL/min/1.73 m², clinicians should consider:

• More conservative initial degludec doses (e.g., 8 to 10 units rather than 10 to 12 units)
• Shorter titration intervals with CGM verification rather than HbA1c-only follow-up
• Quarterly fructosamine if HbA1c reliability is in question due to anemia of CKD or G6PD status

These adjustments are not unique to degludec. They apply to any basal insulin in this population. But degludec's lower nocturnal hypoglycemia rate compared to glargine may offer a relative advantage in CKD patients who are already hypoglycemia-prone 1.

Hypertension, RAAS Inhibitors, and Concurrent Therapy

Black patients with type 2 diabetes frequently require multi-drug antihypertensive regimens. ACE inhibitors and ARBs are first-line for diabetic nephropathy prevention, but Black patients show reduced blood pressure response to RAAS blockade as monotherapy compared to White patients, as documented in ALLHAT (N=33,357) 13. This means Black patients are more likely to be on combination antihypertensive therapy (often including a thiazide diuretic or calcium channel blocker alongside an ACE inhibitor).

Thiazide Diuretics and Glycemic Impact

Thiazide diuretics can worsen insulin resistance and raise fasting glucose by 5 to 15 mg/dL 14. In a patient taking insulin degludec, this effect may manifest as an apparent increase in basal insulin requirements. Clinicians should evaluate whether a rising insulin dose reflects true disease progression or a pharmacologic interaction from an antihypertensive addition before escalating degludec doses.

SGLT2 Inhibitor Coadministration

SGLT2 inhibitors (empagliflozin, dapagliflozin) provide both glycemic and renal protection and are now recommended by KDIGO for diabetic kidney disease regardless of HbA1c 12. When adding an SGLT2 inhibitor to a patient already on degludec, basal insulin doses often need to decrease by 10 to 20% to avoid hypoglycemia. This is true across all racial groups, but the clinical context matters: Black patients with CKD who are starting an SGLT2 inhibitor for renal protection may need proactive degludec dose reduction and closer glucose monitoring during the first 4 to 6 weeks.

Clinical Approach to Titration and Monitoring

Standard degludec titration follows the "treat to target" model. Patients adjust their dose by 2 units every 3 to 4 days based on fasting plasma glucose, targeting 70 to 130 mg/dL per ADA recommendations 6. This algorithm does not change by race. What changes is the monitoring infrastructure and the interpretation of results.

Recommended Monitoring Framework for Black Patients on Degludec

Baseline: Obtain HbA1c, fasting glucose, eGFR, urine albumin-to-creatinine ratio, and CBC. Screen for G6PD deficiency if not previously tested, especially in males. Review current antihypertensive regimen for drugs that may affect glycemia.

Titration phase (weeks 1 to 12): Use fasting glucose values (SMBG or CGM) rather than HbA1c alone to guide dose adjustments. HbA1c measured at week 12 provides a check, but should be interpreted with the 0.3 to 0.4% potential overestimation in mind.

Maintenance (quarterly): Track time-in-range (70 to 180 mg/dL) from CGM data if available. The International Consensus on Time in Range recommends a target of >70% time in range for most adults with type 2 diabetes 15. This metric bypasses the HbA1c-glycation discrepancy entirely.

Annual: Reassess eGFR and albumin-to-creatinine ratio. If eGFR has declined below 45, revisit degludec dosing and hypoglycemia risk as described above.

When to Prefer Degludec Over Glargine

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has stated that "for patients at higher risk of nocturnal hypoglycemia, including those with CKD or erratic meal schedules, the pharmacokinetic stability of degludec offers a clinically meaningful advantage" 16. Black patients with diabetes and CKD represent a population where this advantage may be most relevant, given their compounded hypoglycemia risk from multiple sources.

Sickle Cell Trait and HbA1c Interpretation

Sickle cell trait (HbAS) affects approximately 8 to 10% of Black Americans 17. While sickle cell trait does not cause sickle cell disease, certain HbA1c assay methods (particularly those using boronate affinity chromatography) can produce inaccurate results in the presence of hemoglobin variants. The NGSP (National Glycohemoglobin Standardization Program) maintains a list of assays and their interference profiles.

For patients with known HbAS, clinicians should confirm which HbA1c assay their laboratory uses and whether it is validated for hemoglobin S. If the assay is not validated, fructosamine or CGM-derived glucose management indicator (GMI) should be used instead 6. This is not a degludec-specific issue, but it affects insulin titration safety in a large subset of the Black patient population.

Social Determinants and Access Considerations

Tresiba is a branded insulin with a list price that exceeds $300 per vial in many U.S. Markets. Black adults with diabetes are more likely to be uninsured or underinsured compared to White adults, and cost-related insulin rationing is documented at higher rates in minority populations 18. Insulin rationing increases the risk of diabetic ketoacidosis and hyperglycemic emergencies.

Novo Nordisk offers patient assistance programs, and the Inflation Reduction Act capped insulin copays at $35/month for Medicare Part D enrollees starting in 2023. Clinicians prescribing degludec to Black patients should proactively verify insurance coverage and connect patients with affordability programs before initiating therapy. Switching a patient to degludec for its pharmacokinetic benefits is counterproductive if the patient cannot afford consistent refills.